 |
 |

N-Acetyl-β-Glucosaminidase and β2-MicroglobulinTheir Urinary Excretion in Patients With Renal Parenchymal Disease
Raymond L. Sherman, MD;
Dennis E. Drayer, PhD;
Brian R. Leyland-Jones, MB, BS;
Marcus M. Reidenberg, MD
Arch Intern Med. 1983;143(6):1183-1185.
Abstract
The urinary excretion of N-acetyl-β-glucosaminidase (NAG) and β2-microglobulin (β2M) was studied in 43 patients with various forms of renal parenchymal disease. Patients with membranous nephropathy, membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, obstructive pyelonephritis, nephrosclerosis, and minimal change nephropathy generally had urinary NAG and β2M levels more than 3 SDs above those seen in normal subjects. Patients with progressive renal disease averaged higher NAG and β2M urinary levels than those with the same renal lesion and stable function. Since elevated urinary levels of NAG and β2M suggest renal tubular injury or dysfunction, our observations suggest tubulointerstitial involvement in a wide variety of renal diseases.
(Arch Intern Med 1983;143:1183-1185)
Author Affiliations
From the Departments of Medicine (Drs Sherman, Leyland-Jones, and Reidenberg) and Pharmacology (Drs Drayer and Reidenberg), Cornell University Medical College, New York.
Footnotes
Accepted for publication Feb 4, 1983.
Reprint requests to Department of Medicine, Cornell University Medical College, New York, NY 10021 (Dr Sherman).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Urine proteomics: the present and future of measuring urinary protein components in disease
Barratt and Topham
CMAJ 2007;177:361-368.
ABSTRACT
| FULL TEXT
Nitric oxide activity in childhood hypertension
Goonasekera et al.
Arch. Dis. Child. 1997;77:11-16.
ABSTRACT
| FULL TEXT
|